What iGeneTech does

iGeneTech Bioscience Co., Ltd. is a Beijing-headquartered biotechnology company founded in 2014 that develops next-generation sequencing (NGS) target gene enrichment products and related reagents. Its technology stack rests on three proprietary platforms: liquid-phase NGS probe hybridization, multiplex PCR primer design, and the Ignite 3.0 high-throughput oligo pool synthesis platform (supporting 4k–650k oligo scales at reported 0.2% error rates). The portfolio spans custom and pre-defined capture panels — notably the AIExome V5 family of whole-exome products with Tumor and Inherit Editions — a broad catalog of microbiology (SARS-CoV-2, HBV, EBV, respiratory and GI pathogen panels), oncology (pan-cancer, MRD, hematologic, HRD/HRR), immunology (HLA, immune repertoire), and agricultural (animal and plant exome) panels, plus NGS library preparation kits, hybridization capture reagents, the IGT-AS12 automated liquid handling workstation, and online design tools (Panel Design, IGT Design, MFE Primer).

The company sells primarily through direct B2B channels — website, email, telephone, and WhatsApp — with OEM manufacturing services for partners and lab sequencing services for customers outsourcing testing. Pricing is quote-based and not publicly disclosed. Named customers include the Chinese Center for Disease Control and Prevention, Peking University, and Peking Union Medical College, with international reach supported by an EU IVDD CE mark (SARS-CoV-2 Clinical Amplicon Sequencing Kit, 2021) and participation in industry exhibitions such as MEDICA and BioJapan. Manufacturing operates to ISO 13485 and ISO 9001 standards, and iGeneTech also contributed to drafting a Chinese national standard for forensic NGS reagent quality. Products are validated on Illumina, MGI, Element Biosciences AVITI, and GeneMind SURFSeq platforms.

Revenue derives from one-time sales of NGS reagents and kits, custom and pre-defined panels, OEM/licensing arrangements, professional lab services, and synthetic biology oligo synthesis services. In March 2026 iGeneTech entered a strategic partnership with Tsingke Biotech to integrate gene synthesis capabilities with its Ignite 3.0 platform, targeting precision medicine, bio-breeding, and gene editing markets. The company is privately held, headquartered in Changping District (Beijing) with an operational subsidiary in Jiaxing, Zhejiang.

Name

iGeneTech

Legal name

iGeneTech Bioscience Co., Ltd.

Website

https://igenetech.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

iGeneTech is a Beijing-based biotechnology company founded in 2014 that develops NGS target gene enrichment products — custom and pre-defined panels, library prep reagents, and the AIExome V5 whole-exome family — serving research and clinical customers in oncology, genetic disease, infectious disease, and agricultural genomics.

Ownership category

akta.pro rank

Product category

NGS Target Enrichment Reagents and Panels

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Targeted next-generation sequencing
• NGS target enrichment panels
• Custom hybridization capture probes
• Whole exome sequencing reagents
• NGS library preparation kits

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. NGS Reagents and Kits Sales: Sale of NGS library preparation kits, hybridization capture products, amplicon sequencing products, and universal reagents. Product lines include Enzyme Plus Library Prep Kit, Fast Library Prep Kit, ssDNA Library Prep Kit, Methyl Fast Library Prep Kit, Hyb & Wash Kits, and various adapter/UDI primers.
2. Custom NGS Panels: Full/semi-customization of NGS target enrichment panels including Custom Hybridization Capture panels, Custom Multiplex Amplicon Sequencing panels, and Custom Methyl Hybridization Capture panels.
3. Pre-defined NGS Panels: Ready-to-use panels for various applications including AIExome Human Exome Panels, oncology panels (Leukemia, Lymphoma, NSCLC, Pan-Cancer), microbiology panels (SARS-CoV-2, HBV, EBV), immunology panels (HLA, Immune Repertoire), and animal/plant panels.
4. OEM Services: Customized manufacturing services for other companies requiring gene capture products and reagents.
5. Lab Services: Sequencing services for customers who prefer outsourcing rather than performing in-house testing.
6. Synthetic Biology Services: High-throughput oligo synthesis services through the Ignite 3.0 platform for gene synthesis applications in precision medicine, bio-breeding, and gene editing markets.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

iGeneTech designs, manufactures, and sells NGS target gene enrichment products, including custom and pre-defined probe-based capture panels, amplicon panels, methylation panels, NGS library preparation reagents, hybridization/wash kits, blocking oligos, automation equipment, and OEM and lab sequencing services. Its products serve oncology research, genetic disease testing, infectious disease surveillance, immunology, forensics, and agricultural genomics applications.

Product overview

iGeneTech is a biotechnology company founded in Beijing in 2014, specializing in target gene enrichment and next-generation sequencing (NGS) solutions. The company offers a comprehensive portfolio organized around three core technology platforms: NGS probe hybridization, multiplex PCR primer design, and high-throughput oligo pools synthesis. The product portfolio centers on the AIExome V5 series whole exome panels (including Core, Tumor, and Inherit editions) and spans multiple categories: Custom NGS Panels (hybridization capture, multiplex amplicon sequencing, and methylation capture), Pre-defined NGS Panels for oncology (pan-cancer, solid tumor, hematologic, MRD monitoring), microbiology/pathogens (SARS-CoV-2, respiratory, gastrointestinal syndromes), immunology (HLA, immune repertoire), genetic disorders, and animal/plant genomics; NGS Reagents & Kits for library preparation (Enzyme Plus V3, Fast, ssDNA, Methyl Fast, Long-Read), adapters/indices (UDI primers up to 4,608 types), hybridization capture products (Hyb & Wash Kit v3.0, blocking oligos, streptavidin beads); Equipment (IGT-AS12 Automated Workstation); Software Tools (Panel Design, IGT Design AI primer tool, MFE Primer); and Services (OEM manufacturing, lab services). The company is ISO 13485 and ISO 9001 certified, and its products are compatible with Illumina, MGI, Element Biosciences AVITI, and GeneMind SURFSeq platforms.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• AIExome V5-Inherit achieves 99.92% tested coverage rate for ClinVar pathogenic/likely pathogenic mutation sites
• +6 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

Feature7 records

Partnerships

One partnership is on record.

• Tsingke BiotechflagshipStrategic or Co-development Partner · 10 March 2026Strategic partnership to advance synthetic biology combining Tsingke Biotech's gene synthesis capabilities (from 2nmol laboratory scale to 12mmol industrial scale) with iGeneTech's Ignite 3.0 high-throughput synthesis platform (processing oligo pools from 4k to 650k with error rates as low as 0.2%). The collaboration aims to develop an integrated system spanning from synthesis to application, targeting precision medicine, bio-breeding, and gene editing markets. The partnership was formalized at a signing ceremony at Tsingke Biotech's Beijing headquarters.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Regional players

• MGI Tech: MGI Tech is a leading Chinese sequencing platform provider (DNBSEQ) that offers its own reagent ecosystem, competing with iGeneTech in the Chinese market while iGeneTech's products are validated on MGI sequencers — making MGI both a partner and a regional competitor.
• BGI Genomics: BGI Genomics is a major Chinese genomics service provider and reagent/panel developer, competing with iGeneTech in both the Chinese NGS reagents market and the broader sequencing services market where iGeneTech's lab services and OEM offerings overlap.
• GeneMind Biosciences: GeneMind is a Chinese sequencing instrument maker (SURFSeq 5000) whose CMS Sequencing Kit is validated as compatible with iGeneTech's capture system, positioning it as a regional partner-competitor in the Chinese NGS ecosystem.

Broad incumbents

• Agilent Technologies (SureSelect): Agilent's SureSelect XT and SureSelect Human All Exon products are leading target enrichment solutions globally, competing with iGeneTech's AIExome V5 and custom hybridization capture panels across clinical and translational research customers.
• Illumina: Illumina dominates sequencing instruments and increasingly offers reagents and panels (e.g., TruSight, Illumina DNA Prep), creating both a partnership platform (iGeneTech products are validated on Illumina) and competitive overlap for iGeneTech's reagent and capture panel business.
• Roche (KAPA NGS): Roche's KAPA portfolio of NGS library preparation and target enrichment reagents competes directly with iGeneTech's Enzyme Plus, Fast, and Methyl library prep kits, particularly in clinical sequencing workflows.

Direct peers

• Twist Bioscience: Twist Bioscience is a direct competitor in NGS target enrichment, offering custom DNA capture panels (Twist Target Enrichment) and high-fidelity oligo pools that directly overlap with iGeneTech's hybridization capture and custom panel products for similar genomics research customers.
• Integrated DNA Technologies (IDT): IDT (a Danaher company) is a global leader in NGS library prep reagents, custom panels (xGen), and oligo synthesis — directly competing with iGeneTech's reagent, panel, and capture product lines for academic, clinical, and commercial genomics customers.
• Qiagen (QIAseq): Qiagen's QIAseq Targeted DNA Panels and QIAseq Library Prep kits directly compete with iGeneTech's custom and pre-defined NGS panels (oncology, inherited disease) and library preparation reagents in clinical and translational research workflows.

Emerging players

• NanoString Technologies: NanoString's nCounter and GeoMx platforms offer alternative genomics profiling solutions that partially overlap with iGeneTech's target sequencing approach for spatial transcriptomics and oncology research applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/igenetech
• YouTubeyoutube.com/channel/UCx0ptKpUrTqpvELY52BBYaw
• Facebookfacebook.com/profile.php?id=61555115757941
• LinkedInlinkedin.com/company/igenetech

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iGeneTech